Dupuytren’s Disease: A Comparative Narrative Review of Current Treatment Modalities
DOI:
https://doi.org/10.12775/JEHS.2026.91.70824Keywords
Dupuytren's contracture, Dupuytren's disease, treatment of Dupuytren's disease, limited fasciectomy, dermofasciectomy, open fasciotomy, percutaneous needle fasciotomy, Clostridium collagenase histolyticum injections, Pharmacological therapy, Physical therapyAbstract
Background. Dupuytren’s contracture (DC) is a fibroproliferative disorder of the palmar fascia, characterized by progressive finger flexion deformities and impaired hand function. The condition has a multifactorial etiology, including genetic predisposition, metabolic factors (e.g., diabetes), and environmental factors such as microtrauma and occupational exposure. Its global prevalence is approximately 8%, highlighting the growing clinical need to optimize treatment strategies. The disorder is also frequently observed in athletes, particularly those engaged in sports involving repetitive hand use, such as field hockey.
Objective. The aim of this narrative review is to provide a comprehensive synthesis of current evidence on the treatment of Dupuytren’s contracture (DD). The gathered data are intended to support clinical decision-making by comparing available therapeutic approaches.
Material and methods. A narrative literature review was conducted using PubMed, covering studies published between 2016 and 2026. References in included articles were also screened. The analysis focused on comparing the effectiveness, recurrence, safety, and functional outcomes of surgical, minimally invasive, and non-surgical treatments.
Results. Available evidence indicates that surgical treatment provides the most durable outcomes. Limited fasciectomy remains the reference standard in Dupuytren’s disease, offering the lowest recurrence rates, though it is associated with longer recovery and a higher risk of complications. Minimally invasive approaches enable faster recovery but are associated with higher recurrence rates. Non-surgical and emerging therapies currently lack robust supporting evidence.
Conclusions. Treatment should be individualized, balancing effectiveness, recurrence risk, and recovery time. Further studies are needed to define the role of newer therapies and optimize management strategies
References
1. Grazina R, Teixeira S, Ramos R, Sousa H, Ferreira A, Lemos R. Dupuytren's disease: where do we stand?. EFORT Open Rev. 2019;4(2):63-69. Published 2019 Feb 20. doi:10.1302/2058-5241.4.180021
2. Salari N, Heydari M, Hassanabadi M, et al. The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020;15(1):495. Published 2020 Oct 28. doi:10.1186/s13018-020-01999-7
3. Ball C, Pratt AL, Nanchahal J. Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice. BMC Musculoskelet Disord. 2013;14:131. Published 2013 Apr 10. doi:10.1186/1471-2474-14-131
4. Eftimie G, Eftimie R. Quantitative predictive approaches for Dupuytren disease: a brief review and future perspectives. Math Biosci Eng. 2022;19(3):2876-2895. doi:10.3934/mbe.2022132
5. Layton T, Nanchahal J. Recent advances in the understanding of Dupuytren's disease. F1000Res. 2019;8:F1000 Faculty Rev-231. Published 2019 Feb 28. doi:10.12688/f1000research.17779.1
6. Mansur HG, Oliveira ER, Gonçalves CB. Epidemiological analysis of patients with Dupuytren's disease. Rev Bras Ortop. 2017;53(1):10-14. Published 2017 Dec 14. doi:10.1016/j.rboe.2017.12.003
7. Yuan S, Furniss D, Larsson SC, Leffler DA, Ludvigsson JF. Celiac Disease and Incident Dupuytren's Contracture: A Matched Nationwide Cohort Analysis. Clin Epidemiol. 2025;17:481-484. Published 2025 May 24. doi:10.2147/CLEP.S518939
8. Flatt AE. The Vikings and Baron Dupuytren's disease. Proc (Bayl Univ Med Cent). 2001;14(4):378-384. doi:10.1080/08998280.2001.11927791
9. Ng M, Lawson DJ, Winney B, Furniss D. Is Dupuytren's disease really a 'disease of the Vikings'?. J Hand Surg Eur Vol. 2020;45(3):273-279. doi:10.1177/1753193419882851
10. Broekstra DC, Kuo RYL, Burn E, Prieto-Alhambra D, Furniss D. Dupuytren Disease: Prevalence, Incidence, and Lifetime Risk of Surgical Intervention. A Population-Based Cohort Analysis. Plast Reconstr Surg. 2023;151(3):581-591. doi:10.1097/PRS.0000000000009919
11. van Straalen RJM, de Boer MR, Vos F, Werker PMN, Broekstra DC. The incidence and prevalence of Dupuytren's disease in primary care: results from a text mining approach on registration data. Scand J Prim Health Care. 2025;43(1):173-180. doi:10.1080/02813432.2024.2416678
12. Layton TB, Williams L, Nanchahal J. Dupuytren's disease: a localised and accessible human fibrotic disorder. Trends Mol Med. 2023;29(3):218-227. doi:10.1016/j.molmed.2022.12.001
13. Żyluk A. Dupuytren's disease - what's new: a review. Pol Przegl Chir. 2022;95(6):53-61. doi:10.5604/01.3001.0016.0058
14. Backman M, Nordenskjöld J, Perez R, Rydberg M. Associations of Glycemic Control and Diabetes Duration With Dupuytren Disease in Men and Women With Type 1 and 2 Diabetes. Plast Reconstr Surg Glob Open. 2026;14(1):e7435. Published 2026 Jan 28. doi:10.1097/GOX.0000000000007435
15. Green HD, Burden E, Chen J, et al. Hyperglycaemia is a causal risk factor for upper limb pathologies. Int J Epidemiol. 2024;53(1):dyad187. doi:10.1093/ije/dyad187
16. Burkard T, Lane JCE, Holmberg D, Thorell A, Burden AM, Furniss D. The association of bariatric surgery and Dupuytren's disease: a propensity score-matched cohort study. J Hand Surg Eur Vol. 2022;47(3):288-295. doi:10.1177/17531934211062023
17. Wang Z, Wang Z, Yan Z, Xu Z, Gao A. Smoking, alcohol consumption and risk of Dupuytren's disease: a Mendelian randomization study. BMC Med Genomics. 2023;16(1):212. Published 2023 Sep 7. doi:10.1186/s12920-023-01650-4
18. Broekstra DC, Groen H, Molenkamp S, Werker PMN, van den Heuvel ER. A Systematic Review and Meta-Analysis on the Strength and Consistency of the Associations between Dupuytren Disease and Diabetes Mellitus, Liver Disease, and Epilepsy. Plast Reconstr Surg. 2018;141(3):367e-379e. doi:10.1097/PRS.0000000000004120
19. Pineda N, Ghayyad K, Beaudoin TF, et al. Epidemiology and Treatment Trends in the Management of Dupuytren's Disease From 2016 to 2022. Cureus. 2024;16(10):e72528. Published 2024 Oct 28. doi:10.7759/cureus.72528
20. Noordman MFN, Riesmeijer SA, Werker PMN, Nolte IM. Associations of Demographic, Lifestyle, and Clinical Factors With the Presence of Dupuytren Disease: Results from the Lifelines Cohort Study. J Hand Surg Glob Online. 2025;7(5):100786. Published 2025 Jul 24. doi:10.1016/j.jhsg.2025.100786
21. van den Berge BA, Wiberg A, Werker PMN, Broekstra DC, Furniss D. Dupuytren's disease is a work-related disorder: results of a population-based cohort study. Occup Environ Med. 2023;80(3):137-145. doi:10.1136/oemed-2022-108670
22. Novo J, Gao D, Seth I, Rozen WM. Incidence of Dupuytren's disease following hand trauma: a systematic review. J Hand Surg Eur Vol. 2026;51(1):6-13. doi:10.1177/17531934251360545
23. Broekstra DC, van den Heuvel ER, Lanting R, Harder T, Smits I, Werker PMN. Dupuytren disease is highly prevalent in male field hockey players aged over 60 years. Br J Sports Med. 2018;52(20):1327-1331. doi:10.1136/bjsports-2016-096236
24. Turesson C, Kvist J, Krevers B. Experiences of men living with Dupuytren's disease-Consequences of the disease for hand function and daily activities. J Hand Ther. 2020;33(3):386-393. doi:10.1016/j.jht.2019.04.004
25. Wilburn J, McKenna S, Perry-Hinsley D ...
The Impact of Dupuytren Disease on Patient Activity and Quality of Life
Journal of Hand Surgery, 38, 1209-1214 DOI: 10.1016/j.jhsa.2013.03.036
26. Boe C, Blazar P, Iannuzzi N. Dupuytren Contractures: An Update of Recent Literature. J Hand Surg Am. 2021;46(10):896-906. doi:10.1016/j.jhsa.2021.07.005
27. Eftimie G, Eftimie R. Quantitative predictive approaches for Dupuytren disease: a brief review and future perspectives. Math Biosci Eng. 2022;19(3):2876-2895. doi:10.3934/mbe.2022132
28. Carr L, Michelotti B, Brgoch M, Hauck R, Ingraham J. Dupuytren Disease Management Trends: A Survey of Hand Surgeons. Hand (N Y). 2020;15(1):97-102. doi:10.1177/1558944718787281
29. Lipman MD, Carstensen SE, Deal DN. Trends in the Treatment of Dupuytren Disease in the United States Between 2007 and 2014. Hand (N Y). 2017;12(1):13-20. doi:10.1177/1558944716647101
30. Gordon AM, Nian PP, Miller C, Schwartz JM, Choueka J. Comparison of Patient Demographics, Utilization Trends, and Costs of Treatment for Dupuytren's Disease in the United States From 2012 to 2019. Ann Plast Surg. 2023;91(5):547-552. doi:10.1097/SAP.0000000000003665
31. Ruettermann M, Hermann RM, Khatib-Chahidi K, Werker PMN. Dupuytren's Disease-Etiology and Treatment. Dtsch Arztebl Int. 2021;118(46):781-788. doi:10.3238/arztebl.m2021.0325
32. Hever P, Smith OJ, Nikkhah D. Dupuytren's Fasciectomy: Surgical Pearls in Planning and Dissection. Plast Reconstr Surg Glob Open. 2020;8(7):e2832. Published 2020 Jul 21. doi:10.1097/GOX.0000000000002832
33. Cooper TB, Poonit K, Yao C, Jin Z, Zheng J, Yan H. The efficacies and limitations of fasciectomy and collagenase clostridium histolyticum in Dupuytren's contracture management: A meta-analysis. J Orthop Surg (Hong Kong). 2020;28(2):2309499020921747. doi:10.1177/2309499020921747
34. Denkler K. Surgical complications associated with fasciectomy for dupuytren's disease: a 20-year review of the English literature. Eplasty. 2010;10:e15. Published 2010 Jan 27.
35. Nocek M, Wakefield D, Vitale MA. Likelihood of Dupuytren Contracture Recurrence After Limited Fasciectomy, Needle Aponeurotomy or Collagenase Clostridium histolyticum: Systematic Review of Prospective Data With 2- to 7-Year Follow-up. J Hand Surg Glob Online. 2026;8(3):100979. Published 2026 Mar 5. doi:10.1016/j.jhsg.2026.100979
36. van den Berge BA, Habibi H, Dijkstra PU, et al. Outcomes of limited fasciectomy, needle fasciotomy and collagenase injection for Dupuytren's disease: a systematic review and meta-analysis of individual patient data. J Hand Surg Eur Vol. 2025;50(7):878-890. doi:10.1177/17531934251338349
37. Khaliq F, Orji C. Dupuytren's Contracture: A Review of the Literature. Cureus. 2024;16(12):e74945. Published 2024 Dec 2. doi:10.7759/cureus.74945
38. Walthall J, Anand P, Rehman UH. Dupuytren Contracture. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 26, 2023.
39. Dutta A, Jayasinghe G, Deore S, et al. Dupuytren's Contracture - Current Concepts. J Clin Orthop Trauma. 2020;11(4):590-596. doi:10.1016/j.jcot.2020.03.026
40. Denkler KA, Park KM, Alser O. Treatment Options for Dupuytren's Disease: Tips and Tricks. Plast Reconstr Surg Glob Open. 2022;10(1):e4046. Published 2022 Jan 27. doi:10.1097/GOX.0000000000004046
41. Maruccia M, Tedeschi P, Sisto F, Converti I, Giudice G, Elia R. Dupuytren's Disease: A Novel Minimally Invasive Pull-Through Technique. Arch Plast Surg. 2024;51(3):295-303. Published 2024 Mar 4. doi:10.1055/s-0043-1775882
42. Moog P, Buchner L, Cerny MK, Schmauss D, Megerle K, Erne H. Analysis of recurrence and complications after percutaneous needle fasciotomy in Dupuytren's disease. Arch Orthop Trauma Surg. 2019;139(10):1471-1477. doi:10.1007/s00402-019-03247-y
43. Strömberg J. Percutaneous Needle Fasciotomy for Dupuytren Contracture. JBJS Essent Surg Tech. 2019;9(1):e6. Published 2019 Feb 13. doi:10.2106/JBJS.ST.18.00047
44. Almadani YH, Vorstenbosch J, Efanov JI, Xu L. Dupuytren's Disease: An Outcomes-Focused Update. Semin Plast Surg. 2021;35(3):216-222. doi:10.1055/s-0041-1731631
45. Żyluk A. Management of early stages of Dupuytren's disease: a narrative review. Pol Przegl Chir. 2025;97(5):57-63. doi:10.5604/01.3001.0055.1317
46. Nann S, Kovoor J, Fowler J, et al. Surgical Management of Dupuytren Disease: A Systematic Review and Network Meta-analyses. Hand (N Y). 2024;19(8):1283-1292. doi:10.1177/15589447231174175
47. Seth I, McClure V, Lim B, Cuomo R, Ross RJ, Rozen WM. Collagenase Clostridium Histolyticum Versus Percutaneous Needle Fasciotomy for Dupuytren's Disease: A Systematic Review and Meta-Analysis. Life (Basel). 2025;15(2):259. Published 2025 Feb 8. doi:10.3390/life15020259
48. Räisänen MP, Leppänen OV, Soikkeli J, et al. Surgery, Needle Fasciotomy, or Collagenase Injection for Dupuytren Contracture : A Randomized Controlled Trial. Ann Intern Med. 2024;177(3):280-290. doi:10.7326/M23-1485
49. Cevik J, Rajaram R, Pollock M, Seth I, M Rozen W. Collagenase clostridium histolyticum for Dupuytren's disease: a comprehensive systematic review and comparative analysis against percutaneous needle aponeurotomy and limited fasciectomy. J Plast Surg Hand Surg. 2025;60:27-34. Published 2025 Feb 13. doi:10.2340/jphs.v60.42750
50. Roll SC, Hardison ME. Effectiveness of Occupational Therapy Interventions for Adults With Musculoskeletal Conditions of the Forearm, Wrist, and Hand: A Systematic Review. Am J Occup Ther. 2017;71(1):7101180010p1-7101180010p12. doi:10.5014/ajot.2017.023234
51. Lorenz FM, Henning E, Sicher C, Langner I. Effects of postoperative hand therapy in patients with Dupuytren's disease : A prospective hyperspectral imaging study. Auswirkungen der postoperativen Handtherapie bei Patienten mit Morbus Dupuytren : Eine prospektive Studie zur hyperspektralen Bildgebung. Orthopadie (Heidelb). 2025;54(5):386-394. doi:10.1007/s00132-025-04631-w
52. Yazdani A, Nasri P, Baradaran Mahdavi S. The Effects of Shock Wave Therapy on the Symptoms and Function of Individuals With Dupuytren Disease: A Systematic Review. Arch Phys Med Rehabil. 2024;105(10):1985-1992. doi:10.1016/j.apmr.2024.05.030
53. Ball, C., Izadi, D., Verjee, L.S. et al. Systematic review of non-surgical treatments for early Dupuytren’s disease. BMC Musculoskelet Disord 17, 345 (2016). https://doi.org/10.1186/s12891-016-1200-y
54. Baeri A, Levraut M, Diazzi S, et al. A role for metformin in the treatment of Dupuytren disease?. Biomed Pharmacother. 2022;150:112930. doi:10.1016/j.biopha.2022.112930
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Patrycja Hatala, Aleksandra Grzywacz-Guza, Berenika Kantor, Martyna Gruba, Patrycja Bździuch , Katarzyna Cencelewicz , Aleksandra Lewczuk , Nikodem Mozgała

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 44
Number of citations: 0